The DOI matches its Crossref record; the references it cites are not checked yet.
Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
Open accessAbstract
Background: Homologous recombination (HR) repair deficiency arising from defects in BRCA1 or BRCA2 is associated with characteristic patterns of somatic mutations. In this genetic study, we ask whether inactivating mutations in further genes of the HR pathway or the DNA damage checkpoint also give rise to somatic mutation patterns that can be used for treatment prediction. Results: Using whole genome sequencing of an isogenic knockout cell line panel, we find a universal HR deficiency-specific base substitution signature that is similar to COSMIC signature 3. In contrast, we detect different deletion phenotypes corresponding to specific HR mutants. The inactivation of BRCA2 or PALB2 leads to larger deletions, typically with microhomology, when compared to the disruption of BRCA1, RAD51 paralogs, or RAD54. Comparison with the deletion spectrum of Cas9 cut sites suggests that most spontaneously arising genomic deletions are not the consequence of double-strand breaks. Surprisingly, the inactivation of checkpoint kinases ATM and CHK2 has no mutagenic consequences. Analysis of tumor exomes with biallelic inactivating mutations in the investigated genes confirms the validity of the cell line models. We present a comprehensive analysis of sensitivity of the investigated mutants to 13 therapeutic agents for the purpose of correlating genomic mutagenic phenotypes with drug sensitivity. Conclusion: Our results suggest that no single genomic mutational class shows perfect correlation with sensitivity to common treatments, but the contribution of COSMIC signature 3 to base substitutions, or a combined measure of different features, may be reasonably good at predicting platinum and PARP inhibitor sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig. 4 Classification of large-scale rearrangements. a Total count of large-scale rearrangements in three sequenced genomes per cell line, classified by CREST as interchromosomal translocation (CTX), intrachromosomal translocation (ITX), deletion, or insertion. b The size distribution of large deletions. c Reconstitution of the rearrangement profile of cell lines with > 10 events using 6 rearrangement signatures (Rsig). d Classification of rearrangements in the same cell lines according to categories used for the definition of rearrangement signatures [12]. Rearrangement signature 5 is shown for comparison](https://figures.cochat.ai/paper-figures/1134a0d90d974c729b502cbe09c6b601/correlation-of-homologous-recombination-deficiency-induced-mutational-signatures-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, the 4 patients with RAD51B (n = 2) and XRCC2 (n = 2) deficiency were all predicted to have BRCA2-type HRD, a phenotype shared with RAD51C deficient patients22.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 65 · Cited by 116
Metadata
- Authors
- Póti, Á., Gyergyák, H., Németh, E., Rusz, O., Tóth, S., Kovácsházi, C., Chen, D., Szikriszt, B., Spisák, S., Takeda, S., Szakács, G., Szallasi, Z., Richardson, A. L., & Szüts, D.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- University of Szeged (HU)
- Dana-Farber Cancer Institute (US)
- Kyoto University (JP)
- Johns Hopkins University (US)
- Corresponding author
- Richardson, Andrea L.
- Szüts, Dávid
- ORCID
- Venue
- Genome Biology
- Published
- 2019-11-14
- Volume
- 20
- Issue
- 1
- Pages
- 240-240
- ISSN
- 1465-6906 (ISSN-L)
- 1474-760X
- PMC
- PMC6857305
- OpenAlex
- W2984589472
- Semantic Scholar
- 85c038d7343bc272044c1eaaad0c36e72e2a5e91
- Cited by
- 116
- References
- 65
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 12 · 2023: 25 · 2022: 23 · 2021: 22 · 2020: 16
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Genome biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Research and Technology Innovation Fund of Hungary (K_124881, FIEK_16-1-2016-0005, PD_121381, KTIA_NAP_13-2014-0021, NAP2-2017-1.2.1-NKP-0002)
- Breast Cancer Research Foundation (BCRF-18-137, BCRF-18-159)
- JSPS (Core-to-Core Program)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- homologous recombination deficiency, mutational signatures, PARP inhibitors, drug response prediction, BRCA1, BRCA2, PALB2, RAD51 paralogs, Rad54, ATM, Chk2, DNA damage checkpoint, genomic deletions, microhomology, platinum sensitivity
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Pharmacogenomic Variants, Animals, Cell Line, Chickens, Drug Screening Assays, Antitumor, Humans, Mutagenesis, Point Mutation, Genes, cdc, Recombinational DNA Repair
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. https://app.cochat.ai/papers/10.1186/s13059-019-1867-0
- The paper
- Póti, Á., Gyergyák, H., Németh, E., Rusz, O., Tóth, S., Kovácsházi, C., Chen, D., Szikriszt, B., Spisák, S., Takeda, S., Szakács, G., Szallasi, Z., Richardson, A. L., & Szüts, D. (2019). Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. Genome Biology. https://doi.org/10.1186/s13059-019-1867-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.